Should You Be Taking Gabapentin for Pain?

But is gabapentin really an effective option for pain relief? The answer depends on the type of pain — along with a few other factors. Here’s what experts say about gabapentin, its recommended uses, potential risks and side effects, and who might want to try it.
What Is Gabapentin?
- Partial Seizures To help calm overactive brain cells
- Postherpetic Neuralgia (PHN) To ease nerve pain after shingles
- Restless Legs Syndrome (RLS) To reduce uncontrollable leg movements during sleep, with only the Horizant formulation approved for this purpose
So how did gabapentin become commonly used off-label for other types of pain — despite not having FDA approval for those conditions?
How Gabapentin Works for Pain
What Type of Pain Does Gabapentin Help With?
- Postherpetic neuralgia pain (PHN), or nerve pain that happens after a shingles infection occurs, is an FDA-approved use of gabapentin, which is available in capsule, tablet, and oral solution form. It’s considered to be a first-line option for this shingles complication.
- Restless legs syndrome (RLS), a condition that causes uncontrollable movement and painful sensations in the legs. Current medical guidelines from the American Academy of Sleep Medicine strongly recommend gabapentin as part of RLS treatment.
- Diabetic neuropathy pain, or pain that occurs as a result of damaged nerves from high blood sugar levels, may benefit from gabapentin. While gabapentin is not FDA-approved for this purpose, it’s still recommended by the diabetes professional medical association, and physicians often utilize it as a first-line treatment in these cases.“There is general consensus of effectiveness for gabapentin when used for painful diabetic neuropathy — though not without caveats,” Growdon says.
While clinicians and patients report that gabapentin may be effective at calming nerve pain for non-FDA-approved conditions like diabetic neuropathy, more scientific evidence is needed before it can be broadly — and officially — recommended. “The off-label use of gabapentin is commonplace for nerve pain conditions; however, specific studies for other pain conditions may be more limited despite its [possible] efficacy,” says Dr. Liao.
Risks and Side Effects
- Drowsiness
- Dizziness
- Headache
- Blurry vision
- Coordination difficulties
- Weight gain
- Swollen hands, legs, and feet
- Nausea or vomiting
- Fever
- Memory loss or confusion
- Difficulty speaking
- Double vision or unusual eye movements
- Skin rash or hives
- Swelling of the face, tongue, throat, lips, or eyes
- Difficulty swallowing or breathing
- Seizures
- Abnormal changes in mood or behavior
- Trouble urinating, dark-colored urine, or blood in your urine
- Yellowing of the skin and eyes (jaundice)
- Bluish tint to lips, skin, and nail bed color
“We know that taking three or more centrally nervous system active medications increases the risk of falls in older adults, which can be a major cause of morbidity and even mortality among older adults,” Growdon explains.
- Older adults, as the medication can increase drowsiness and risk of falling
- People with lung or respiratory conditions, as it can lead to serious breathing issues
- People with kidney disease, as it may not clear the body properly, which could lead to toxicity
- People who are pregnant, as while human research is limited, some evidence suggests a potential link to a higher risk of birth impacts, particularly in late pregnancy As with other medications, gabapentin use should be discussed in consultation with your healthcare provider to assess individualized safety during pregnancy.
Who Might Benefit From Gabapentin?
Gabapentin may be a pain management treatment option for people with nerve pain-related conditions. “Patients with nerve-related pain conditions are potential candidates for gabapentin; however, evaluation by a medical professional is necessary before it can be prescribed,” Liao says.
But even if you’ve been diagnosed with neuropathic pain, it’s important to ask your healthcare provider about the specific potential risks and possible benefits of gabapentin.
“When discussing chronic pain with a primary care physician, focus on how the pain has changed your ability to do your activities of daily living, sleep, or exercise, and what an effective treatment would look like for you,” MacKenzie says.
In addition, a healthcare provider can advise you about available pain management approaches — including other nerve pain medications, physical therapy, topical treatments, and lifestyle modifications.
“Medication may be one part of this, but mindfulness, physical therapy, acupuncture, and other modalities may be effective ways to control pain without the side effects of medication,” says MacKenzie. “Sometimes, medication does help patients — even when prescribed off-label, like gabapentin. It is important to have a reward-risk discussion with your doctor to see if it is the right fit for you.”
The Takeaway
- Gabapentin is a prescription medication that’s FDA-approved to treat partial seizures, postherpetic nerve pain from shingles, and restless leg syndrome (for which only the Horizant formulation is an approved treatment).
- In recent decades, healthcare professionals have prescribed it off-label to treat other types of pain and conditions, such as low back pain, migraine, and more, though more research is needed to confirm its efficacy for these unapproved conditions.
- Despite its off-label uses, research suggests that gabapentin is most effective for nerve-related (neuropathic) pain.
- If you’re experiencing pain, experts recommend consulting with a healthcare provider about which treatment options may be best for you.
- Gabapentin. MedlinePlus. May 15, 2020.
- Combs KG et al. A Comprehensive Analysis of Jurisdiction-Specific Laws Related to Scheduling or Required Prescription Drug Monitoring of Gabapentin in the United States, 2016–2024. The International Journal on Drug Policy. December 5, 2025.
- Gabapentin (Trade Name: Neurontin®). Drug Enforcement Administration. March 2025.
- Growdon ME et al. Decision-Making and Downstream Outcomes of the Gabapentinoid-Diuretic Prescribing Cascade. JAMA Network Open. December 2, 2025.
- Yasaei R et al. Gabapentin. StatPearls. February 21, 2024.
- Soliman N et al. Pharmacotherapy and Non-Invasive Neuromodulation for Neuropathic Pain: A Systematic Review and Meta-Analysis. The Lancet. May 2025.
- What Are Opioids. American Society of Anesthesiologists.
- Petryna O. NSAIDs (Nonsteroidal Anti-Inflammatory Drugs). American College of Rheumatology. February 2024.
- Yasaei R et al. Gabapentin. StatPearls. February 21, 2024.
- Lampl L et al. The Comparative Effectiveness of Migraine Preventive Drugs: A Systematic Review and Network Meta-Analysis. The Journal of Headache and Pain. May 19, 2023.
- Ward J et al. A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain. Drugs. October 26, 2024.
- Russo M et al. Gabapentin — Friend or Foe? Pain Practice. October 27, 2022.
- Neurontin. U.S. Food and Drug Administration. March 1, 2011.
- Beben D et al. Post-herpetic Neuralgia: Currently Available Oral and Topical Medications in the Management of Pain – A Review. Journal of Pre-Clinical and Clinical Research. June 14, 2024.
- Winkelman JW et al. Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine. January 1, 2025.
- Retinopathy, Neuropathy, and Foot Care: Standards of Medical Care in Diabetes – 2022. Diabetes Care. December 16, 2021.
- Wiffen PJ et al. Gabapentin For Chronic Neuropathic Pain in Adults. The Cochrane Database of Systematic Reviews. June 9, 2017.
- Gabapentin. Cleveland Clinic. July 1, 2021.
- FDA Warns About Serious Breathing Problems With Seizure and Nerve Pain Medicines Gabapentin (Neurontin, Gralise, Horizant) and Pregabalin (Lyrica, Lyrica Cr). U.S. Food and Drug Administration. December 19, 2019.
- McNeilage AG et al. Experiences of Misuse and Symptoms of Dependence Among People Who Use Gabapentinoids: A Qualitative Systematic Review. International Journal of Drug Policy. November 2024.
- Neurontin. U.S. Food and Drug Administration. October 2017.
- Patorno E et al. Gabapentin in Pregnancy and the Risk of Adverse Neonatal and Maternal Outcomes: A Population-based Cohort Study Nested in the US Medicaid Analytic Extract Dataset. PLOS Medicine. September 1, 2020.
- RA Nunge et al. Pain Medication Use During Pregnancy. Seminars in Perinatology. June 2025.
- Good Health Before Pregnancy: Prepregnancy Care. American College of Obstetricians and Gynecologists. October 2025.

Kristina D. Carter, PharmD
Medical Reviewer
Kristina D. Carter, PharmD, is a clinical pharmacist and freelance health writer who currently works in a managed care setting, performing quality audits on utilization management case reviews for the pharmacy team. She has over 20 years of experience and has worked in several pharmacy practice settings, including at a community pharmacy as well as in ambulatory care, senior care, and pharmacy operations.
She received her doctor of pharmacy degree from Xavier University of Louisiana College of Pharmacy and her master's of business administration and health administration from Georgia State University Robinson College of Business. She is an American Council on Exercise–certified health coach, group fitness instructor, senior fitness specialist, and weight management specialist. She is also a registered pharmacist, licensed in Georgia, Indiana, and Tennessee.
Dr. Carter enjoys exploring new restaurants with family and friends, walking along city trails, and watching action movies and college sports.

Cristina Mutchler
Author
Cristina Mutchler is an award-winning journalist with more than a decade of experience covering health and wellness content for national outlets. She previous worked at CNN, Newsy, and the American Academy of Dermatology. A multilingual Latina and published bilingual author, Cristina has a master's degree in Journalism from the E.W. Scripps School of Journalism at Ohio University.